Clinical Trials Logo

Clinical Trial Summary

Hepatic dysfunction limits the therapeutic options for hepatocellular carcinoma (HCC), which is closely associated with patient prognosis. Established practice guidelines for patients with HCC and impaired liver function are lacking. The treatment allocation in these populations is heterogeneous and remains controversial. This study compared the survival benefits of liver resection (LR) and transarterial chemoembolisation (TACE) in patients with HCC and impaired liver function.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06245785
Study type Observational
Source Tang-Du Hospital
Contact
Status Completed
Phase
Start date January 1, 2023
Completion date December 1, 2023

See also
  Status Clinical Trial Phase
Completed NCT01906021 - Study of New Software Used During Ablations N/A
Withdrawn NCT01882218 - Direct Peritoneal Resuscitation Plus Conventional Resuscitation Phase 4
Active, not recruiting NCT04813432 - Multiple Arterial Phase Computed Tomography Examination to Improve Detection of Tumors in the Liver and Pancreas
Recruiting NCT04609410 - Bleeding in Laparoscopic Liver Surgery N/A
Recruiting NCT04517448 - Quality of Life of Patients Over 75 Yars Undergoing Palliative Chemotherapy
Terminated NCT01862718 - Fusion Guided Thermal Ablation Combined With External Beam Radiation for Hepatic Neoplasms Phase 1
Recruiting NCT04028479 - The Registry of Oncology Outcomes Associated With Testing and Treatment
Recruiting NCT03623464 - RCT of Mobile Apps & FitBit v. Usual Care N/A
Recruiting NCT05788484 - A Study of CDX-585 in Patients With Advanced Malignancies Phase 1
Recruiting NCT06342414 - An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer
Terminated NCT00669136 - Immunization With AFP + GM CSF Plasmid Prime and AFP Adenoviral Vector Boost in Patients With Hepatocellular Carcinoma Phase 1
Completed NCT00587067 - A Phase II Study of Continuous Hepatic Arterial Infusion With Floxuridine (FUDR) and Dexamethasone (DEX) in Patients With Unresectable Primary Hepatic Malignancy Phase 2
Completed NCT00187109 - Recombinant Human Thrombopoietin in Children Receiving Ifosfamide, Carboplatin, and Etoposide Chemotherapy Phase 1/Phase 2
Completed NCT02191761 - Safety and Pharmacokinetics of SM04755 in Subjects With Advanced Colorectal, Gastric, Hepatic, or Pancreatic Cancer Phase 1
Completed NCT01033240 - CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer Phase 2
Recruiting NCT04764409 - Prevention and Treatment of Complications of Endovascular Methods in Patients With Malignant Liver Tumors
Completed NCT02649868 - LC Bead LUMI Radio-Opaque Embolic Beads to Detect and Characterize the Vascularity of Hepatic Tumors During Treatment With Transarterial Embolization (TAE) Alone or Combined With Thermal Ablation Phase 2
Terminated NCT00923052 - The Natural History of Solid Organ Cancer Stem Cells (SOCSC)
Recruiting NCT05957822 - Goal-directed vs Preemptive Tranexamic Acid Administration in Non-cardiac Surgery Phase 4
Completed NCT02834780 - Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma Phase 1